Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lineage Cell Therapeutics, Inc. (DE:BT3)
FRANKFURT:BT3
Lineage Therap (BT3) Stock Price & Analysis
0 Followers
BT3 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.78 - €1.39
Previous Close€0.96
Volume0.00
Average Volume (3M)1.28K
Market Cap
€227.98M
Enterprise Value€196.46M
Total Cash (Recent Filing)$35.49M
Total Debt (Recent Filing)$2.95M
Price to Earnings (P/E)N/A
Beta0.28
Next Earnings
May 09, 2024EPS Estimate
-€0.04Last Dividend Ex-Date
Nov 29, 2018Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding188,533,536
10 Day Avg. Volume9
30 Day Avg. Volume1,278
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)32.31
Price to Sales (P/S)20.34
Price to Cash Flow (P/CF)-8.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue22.10
Enterprise Value/Gross Profit23.74
Enterprise Value/Ebitda-13.17
Forecast
1Y Price Target
€4.88Price Target Upside407.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Lineage Therap News
PremiumPre-Earnings
Is LCTX a Buy, Before Earnings?
PremiumStock Analysis & Ideas
These 2 ‘Strong Buy’ Penny Stocks Could Go Boom, Say Analysts
PremiumCompany Announcements
Lineage Cell Therapeutics Announces Early Shareholder Meeting
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.15% Other Institutional Investors
99.85% Public Companies and
Individual Investors
BT3 FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was €0.78 and its highest was €1.39 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is May 09, 2024 which is tomorrow.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on Mar 07, 2024. The company reported -€0.028 earnings per share for the quarter, beating the consensus estimate of -€0.04 by €0.012.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. pays a Notavailable dividend of €0.1 which represents an annual dividend yield of N/A. See more information on Lineage Cell Therapeutics, Inc. dividends here
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -€0.04.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Currently, no data Available
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -€0.028 in its last earnings report, beating expectations of -€0.04. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Among the largest hedge funds holding Lineage Cell Therapeutics, Inc.’s share is Defender Capital, LLC.. It holds Lineage Cell Therapeutics, Inc.’s shares valued at 5M.
---
Lineage Therap Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€4.88 (407.98% Upside)
€4.88 (407.98% Upside)
Blogger Sentiment
Bullish
DE:BT3 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $7.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.09%
12-Months-Change
Fundamentals
Return on Equity
-31.42%
Trailing 12-Months
Asset Growth
-18.31%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.
---
BT3 Earnings Call
Q4 2024
0:00 / 0:00
---
BT3 Stock 12 Months Forecast
Average Price Target
€4.88
▲(407.98% Upside)
Technical Analysis
Lineage Therap
―
Plus Therapeutics
―
Advaxis
―
Brainstorm Cell Therapeutics
―
Traws Pharma
―
Best Analysts Covering BT3
1 Year
1 Year Success Rate
5/15 ratings generated profit
1 Year Average Return
-3.51%
reiterated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -3.51% per trade.
---